Literature DB >> 25441683

High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication.

Theodore S Gourdin1, Ying Zou2, Yi Ning2, Ashkan Emadi1, Vu H Duong1, Michael L Tidwell1, Ching Chen2, Feyruz V Rassool3, Maria R Baer4.   

Abstract

FLT3 internal tandem duplication (ITD) mutations are present in acute myeloid leukemia (AML) in 30% of patients with acute myeloid leukemia (AML), most commonly in those with a normal karyotype, and are associated with short relapse-free survival. Both in vitro and in vivo studies of FLT3-ITD cell lines have demonstrated reactive oxygen species-mediated DNA double-strand breaks and associated error-prone DNA repair as a mechanism of genomic instability, and we hypothesized that genomic instability might be manifested by cytogenetic changes at relapse of FLT3-ITD AML. We retrospectively reviewed charts of patients with cytogenetically normal (CN) FLT3-ITD AML treated at the University of Maryland Greenebaum Cancer Center, with attention to metaphase analysis results at relapse. Cytogenetic data were available from first and, when applicable, subsequent relapses for 15 patients diagnosed with CN FLT3-ITD AML. Among 12 patients with documented FLT3-ITD at first and, when applicable, subsequent relapse, 10 had cytogenetic changes, including nine with rare structural abnormalities. The high frequency of rare structural chromosome abnormalities at relapse in our case series supports a role of genomic instability in the genesis of relapse, and suggests that reactive oxygen species-generating and DNA repair pathways might be therapeutic targets in FLT3-ITD AML.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; FLT3-ITD; cytogenetics; genomic instability; relapse

Mesh:

Substances:

Year:  2014        PMID: 25441683      PMCID: PMC7486681          DOI: 10.1016/j.cancergen.2014.09.001

Source DB:  PubMed          Journal:  Cancer Genet


  31 in total

1.  Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Authors:  Kathleen M Murphy; Mark Levis; Michael J Hafez; Tanya Geiger; Lisa C Cooper; B Douglas Smith; Donald Small; Karin D Berg
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.

Authors:  Ulrike Bacher; Torsten Haferlach; Tamara Alpermann; Melanie Zenger; Andreas Hochhaus; Dietrich W Beelen; Michael Uppenkamp; Mathias Rummel; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

3.  FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology.

Authors:  Stanley R McCormick; Matthew J McCormick; Patricia S Grutkoski; Gregory S Ducker; Nilanjana Banerji; Rodney R Higgins; John R Mendiola; John J Reinartz
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

4.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

Authors:  Sonali M Smith; Michelle M Le Beau; Dezheng Huo; Theodore Karrison; Ronald M Sobecks; John Anastasi; James W Vardiman; Janet D Rowley; Richard A Larson
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

5.  FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.

Authors:  Takashi Sato; Xiaochuan Yang; Steven Knapper; Paul White; B Douglas Smith; Steven Galkin; Donald Small; Alan Burnett; Mark Levis
Journal:  Blood       Date:  2011-01-24       Impact factor: 22.113

6.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.

Authors:  S M Sengsayadeth; M Jagasia; B G Engelhardt; A Kassim; S A Strickland; S Goodman; C Lucid; C L Vnencak-Jones; J P Greer; B N Savani
Journal:  Bone Marrow Transplant       Date:  2012-06-04       Impact factor: 5.483

8.  Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse.

Authors:  O M Garson; A Hagemeijer; M Sakurai; B R Reeves; G J Swansbury; G J Williams; G Alimena; D C Arthur; R Berger; A de la Chapelle
Journal:  Cancer Genet Cytogenet       Date:  1989-07-15

Review 9.  Emerging paradigms in cancer genetics: some important findings from high-density single nucleotide polymorphism array studies.

Authors:  Manny D Bacolod; Gunter S Schemmann; Sarah F Giardina; Philip Paty; Daniel A Notterman; Francis Barany
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

10.  Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients.

Authors:  Fernando L A Fonseca; Aleksandra V L Sant Ana; Israel Bendit; Vitor Arias; Luciano J Costa; Aparecida A Pinhal; Auro del Giglio
Journal:  Breast Cancer Res       Date:  2004-11-04       Impact factor: 6.466

View more
  3 in total

Review 1.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

Review 2.  Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.

Authors:  Anna J Dellomo; Maria R Baer; Feyruz V Rassool
Journal:  Cancer Lett       Date:  2019-04-04       Impact factor: 8.679

Review 3.  FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.

Authors:  Maria Larrosa-Garcia; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2017-06       Impact factor: 6.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.